first-pass

I just wanted a read on the first-pass prime suspects.

There is no clear evidence of any first-pass metabolism.

Avoiding first-pass metabolism allows more of the drug to be available for treatment.

These are mainly for drugs without much first-pass liver metabolism.

Especially the latter two enzymes contribute significantly to the first-pass effect.

The first-pass effect can also be exploited for a beneficial effect.

It also avoids the first-pass effect in the liver.

After oral administration its bioavailability is about 0.34, due to a substantial first-pass effect.

It has a high first-pass metabolism, which results in a poor bioavailability when taken orally.

However, due to extensive first-pass metabolism, only a relatively small amount enters systemic circulation.

The strong first-pass hepatic metabolism results in poor bioavailability.

As a result, the amount of the drug in its original form that reaches systemic circulation is reduced due to this first-pass metabolism.

A first-pass scan can be used in children to look for heart problems that have been present since birth (congenital heart disease).

Erdosteine contains two blocked sulfhydryl groups which are released following first-pass metabolism.

This is likely because of extensive first-pass metabolism by the enzyme monoamine oxidase.

Pentobarbital undergoes first-pass metabolism in the liver and possibly the intestines.

Despite complete absorption, propranolol has a variable bioavailability due to extensive first-pass metabolism.

MUGA scanning may be done after a first-pass scan.

Given first-pass approval.

Over 90% undergo first-pass metabolism.

A multivariate ordination algorithm is applied to derive a first-pass hypothesized sequence of first and last appearances.

Clarithromycin has a fairly rapid first-pass hepatic metabolism.

The absorption of clozapine is almost complete, but the oral bioavailability is only 60 to 70% due to first-pass metabolism.

Valaciclovir is then converted to Aciclovir by esterases via hepatic first-pass metabolism.

In drug design, drug candidates may have good druglikeness but fail on first-pass metabolism, because it is biochemically selective.